Humulin M3 (Insulin Human (Rdna))

Humulin M3 is prescribed to improve glycemic control in adults and children with diabetes.

• As basal insulin in combination with meals for type 1 diabetes.
• To cover mealtime (prandial) glucose spikes in type 2 diabetes when diet and oral agents are insufficient.
• For patients who prefer a twice‑daily injection schedule.
• In insulin‑treated patients requiring a predictable mix of short‑acting and intermediate‑acting insulin.
• May be used during pregnancy under medical supervision (category B).

• Humulin M3 contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and enhancing glucose uptake. In the liver, insulin suppresses gluconeogenesis and stimulates glycogen synthesis, thereby lowering circulating glucose levels. Overall, the combined rapid and intermediate action of the premixed formulation provides both immediate post‑prandial and sustained basal insulin activity.

Like other insulin preparations, Humulin M3 may cause adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose), which may present as shakiness, sweating, confusion, or dizziness.
• Injection‑site reactions such as mild redness, swelling, itching or bruising.
• Lipodystrophy, including localized fat accumulation (lipohypertrophy) or loss (lipoatrophy) at the site of repeated injections.
• Gradual weight gain that can accompany improved glycemic control and increased caloric storage.

Serious

• Severe hypoglycemia resulting in loss of consciousness, seizures, or the need for external glucose administration.
• Allergic responses ranging from urticaria and angioedema to rare anaphylactic shock.
• Persistent hyperglycemia or ketoacidosis suggesting inadequate insulin effect or resistance.
• Fluid retention, peripheral edema, or worsening heart failure in patients with cardiac disease.

Healthcare providers should consider several precautions before prescribing Humulin M3 to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review patient’s history of hypoglycemia unawareness or recurrent episodes.
• Adjust doses during periods of illness, surgery, or changes in physical activity.
• Monitor blood glucose closely during pregnancy; insulin requirements often change.
• Avoid use in patients with known hypersensitivity to recombinant human insulin or any excipients.
• Caution in the elderly, who may have variable absorption and increased risk of hypoglycemia.
• Educate patients on proper injection technique and rotation of sites.

Humulin M3 can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of high‑dose sulfonylureas or meglitinides, which may precipitate severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms and may blunt recovery.

Use with caution

• Corticosteroids, thiazide diuretics, and growth hormone, which can raise blood glucose and require dose adjustments.
• ACE inhibitors and ARBs, which may enhance insulin sensitivity and increase hypoglycemia risk.
• Oral contraceptives or hormone replacement therapy, potentially altering insulin requirements.
• Alcohol consumption, especially in excess, which can cause unpredictable glucose fluctuations.